Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- Palliative care in ATTR-CM runs alongside disease-modifying treatment rather than replacing it at the end.
- Symptom and congestion management remain central as functional capacity declines.
- Advance care planning lets patients define goals before a crisis forces decisions.
- Advanced disease prompts conversations about specialist palliative care, hospice timing, and device deactivation.
Palliative Care Runs Alongside Disease-Modifying Treatment
Palliative care in ATTR-CM is most useful when it’s integrated early and concurrently, not reserved for the final phase of illness. Because the disease is chronic and progressive, a focus on symptom relief, quality of life, and patient priorities is relevant throughout the disease course and continues even while disease-modifying therapy is being given. Framed this way, palliative care complements rather than competes with active treatment, and it supports the continuity of care relationship that’s central to long-term ATTR-CM management.
Symptom and Congestion Management as Function Declines
Much of the day-to-day palliative work in ATTR-CM overlaps with good heart failure care. Managing congestion, breathlessness, fatigue, and the functional limitations that accompany progressive disease is central to maintaining quality of life, regardless of where the patient is in the course. As function declines, the emphasis often shifts toward comfort and the burdens of treatment, and ongoing serial assessment helps the team adjust supportive care in step with the patient's changing condition.
Advance Care Planning and Goals of Care
Advance care planning gives patients the chance to define what matters to them before a crisis narrows the options. Conversations about goals of care, preferences for escalation or de-escalation of treatment, and the trade-offs the patient is willing to accept are most valuable when they happen while the patient can participate fully. Revisiting these discussions periodically, rather than once, keeps the plan aligned with the patient's evolving condition and priorities and supports collaborative decision-making throughout the disease course.
When to Involve Specialist Palliative Care, Hospice, and Device Decisions
As ATTR-CM advances, several specific questions come into focus. The team weighs whether continuing disease-modifying therapy still serves the patient's goals, when specialist palliative care or hospice would add value based on overall disease trajectory, symptom burden, prognosis, and patient goals, and how to manage device-related decisions such as deactivation of an implantable cardioverter-defibrillator (ICD) to avoid unwanted shocks near the end of life. These are general principles of advanced heart failure care applied to ATTR-CM, and they’re best handled proactively and collaboratively with the patient and family, rather than deferred until a clinical decompensation makes them urgent.
Practical Palliative and Planning Checklist
Across the ATTR-CM course, revisit:
- Is symptom and congestion management keeping pace with functional decline?
- Has advance care planning happened while the patient can participate fully?
- Do current treatments still align with the patient's stated goals?
- Would specialist palliative care or hospice add value at this stage?
- Have device decisions, including defibrillator deactivation, been discussed proactively?
Clinical Decision Point
The central judgment in advanced ATTR-CM is how to balance disease-modifying therapy against comfort and goals of care as the disease progresses. Palliative care isn't the moment treatment stops; it’s the framework that keeps symptom relief, advance planning, and device decisions in view throughout. Addressing these conversations proactively—while the patient retains decision-making capacity—is more likely to result in care that reflects the patient's goals and values.
Frequently Asked Questions
When should palliative care begin in ATTR-CM?
Palliative care is most useful when integrated early and concurrently with disease-modifying treatment, not reserved for the final phase. Because ATTR-CM is progressive, attention to symptom relief and quality of life is relevant from diagnosis onward.
Does palliative care mean stopping disease-modifying therapy?
No. Palliative care runs alongside active treatment. Whether to continue disease-modifying therapy as disease advances is a separate goals-based decision, and the two approaches are complementary rather than mutually exclusive.
Why is advance care planning important in ATTR-CM?
Advance care planning matters because it lets patients define their goals and preferences before a crisis narrows the options. Planning while the patient can participate fully and revisiting it over time keeps care aligned with the patient's evolving priorities.
What about defibrillator deactivation?
In advanced disease, deactivating an implantable defibrillator may be considered to avoid unwanted shocks near the end of life. This is part of advance care planning and is best discussed proactively with the patient and family as a goals of care decision.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Manage the Disease
Next Clinical Decision
See the Evidence
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Current Treatment Decisions in Cardiac Transthyretin Amyloidosis: A Multicentre Analysis. Clinical Research in Cardiology
This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.